A tumor marker blood test measures specific proteins or other substances in your blood that cancer cells, or sometimes normal cells responding to cancer, produce in unusually high amounts. These tests are most commonly used to track how well cancer treatment is working, check for cancer recurrence, or help support a diagnosis alongside other tests. They are rarely used on their own to confirm or rule out cancer.
How Tumor Markers End Up in Your Blood
Both healthy cells and cancer cells produce proteins and release them into the bloodstream. The difference is that cancer cells tend to produce certain proteins at much higher levels than normal cells do. When tumors grow, they also shed cells and fragments of biological material into the blood, raising the concentration of these substances to detectable levels.
A standard blood draw is all that’s needed. The sample goes to a lab, where it’s measured against a reference range. For example, the normal range for CEA (a marker linked to colorectal cancer) is typically 0 to 5 units per milliliter. CA-125, associated with ovarian cancer, is considered normal below 35 units per milliliter. A result above these cutoffs doesn’t automatically mean cancer is present, but it signals the need for further investigation.
What These Tests Are Actually Used For
The most common reason your doctor orders a tumor marker test is to monitor a cancer that’s already been diagnosed. During treatment, your medical team will draw blood at regular intervals to see whether marker levels are rising or falling. Dropping levels generally suggest treatment is working and the tumor is shrinking. Rising levels can indicate the cancer is growing, spreading, or not responding to the current approach.
After treatment ends, tumor marker tests serve as an early warning system for recurrence. If levels start climbing months or years after treatment, it can signal that cancer has returned before symptoms appear or imaging picks anything up.
Some markers also help with initial diagnosis, though always alongside other evidence like imaging or biopsy results. PSA, for instance, is used to help identify prostate cancer. CA-125 plays a role in evaluating ovarian cancer. Alpha-fetoprotein (AFP) helps diagnose liver cancer and certain germ cell tumors. But none of these markers can diagnose cancer by themselves.
Common Markers and Their Cancer Types
- PSA (prostate-specific antigen): Prostate cancer. Used to help with diagnosis, monitor treatment response, and watch for recurrence.
- CA-125: Ovarian cancer. Helps evaluate diagnosis, treatment response, and recurrence.
- CEA (carcinoembryonic antigen): Colorectal cancer and some other cancers. Primarily used to check whether treatment is effective and to detect recurrence.
- AFP (alpha-fetoprotein): Liver cancer, ovarian cancer, and germ cell tumors. Helps with diagnosis, staging, and monitoring treatment.
- CA 19-9: Pancreatic, gallbladder, bile duct, and stomach cancers. Mainly used to assess whether treatment is working.
Why an Elevated Result Doesn’t Always Mean Cancer
One of the biggest limitations of tumor marker tests is that noncancerous conditions can raise the same proteins. CEA levels, for example, can be elevated in people with inflammatory bowel disease, chronic lung conditions like COPD, liver dysfunction, gallbladder inflammation, and peptic ulcer disease. Smoking alone can push CEA levels above the normal range. In one documented case, a patient’s elevated CEA normalized completely after gallbladder surgery for chronic inflammation, with no cancer involved at all.
This is why oncology guidelines recommend against using most tumor markers as standalone screening tests for the general population. The rate of false positives is too high. An elevated result in someone without cancer can trigger anxiety, unnecessary imaging, and even invasive procedures like biopsies that turn out to be unnecessary. Professional guidelines from organizations like ASCO explicitly recommend against using certain marker tests for screening in healthy, asymptomatic people.
False negatives are also possible. Some cancers simply don’t produce elevated levels of any known marker, especially in early stages. A normal result does not guarantee you’re cancer-free.
What the Test Experience Is Like
Getting a tumor marker blood test is no different from any routine blood draw. A needle goes into a vein in your arm, a few tubes of blood are collected, and you’re done in minutes. Most tumor marker tests don’t require fasting or any special preparation beforehand. Results typically come back within a few days, depending on the lab.
What matters more than any single result is the trend over time. A single elevated reading is far less meaningful than a pattern of rising or falling numbers across multiple tests. Your oncologist will typically order these tests on a schedule, comparing each new result against your personal baseline rather than judging any one number in isolation.
Newer Blood-Based Tests
Traditional tumor markers are proteins, but a newer category of blood tests looks for fragments of DNA that tumors release into the bloodstream. These circulating tumor DNA tests, sometimes called liquid biopsies, have some notable advantages. Because the DNA fragments come directly from tumor cells and carry the same genetic mutations, they’re more specific to cancer and less likely to be elevated by benign conditions like inflammation or smoking.
Tumor DNA also breaks down in the bloodstream much faster than proteins, with a half-life under two and a half hours compared to several days for protein markers. That shorter lifespan makes these tests more sensitive to rapid changes in tumor size, giving a more real-time picture of whether treatment is working. They can also identify specific gene mutations in the tumor, which helps doctors choose targeted therapies and detect when a cancer develops resistance to a current treatment. Protein markers can’t provide that kind of information.
The tradeoffs are practical. DNA-based tests are more expensive, less widely available, take longer to process, and aren’t as well standardized across laboratories. For now, traditional protein markers remain the workhorse of routine cancer monitoring, while liquid biopsies are increasingly used in specific clinical situations where their precision matters most.